MYGN · Myriad Genetics Inc · Documents
$6.63
+0.00 (+0.00%)
At close · Oct 29
Return incl. dividend (before tax)
Q2 2026 earnings call transcript
Market Cap
$634.16M
Shares
95.65M
Volume · Oct 29
414.26K
Avg daily vol (3M)
2.63M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | On October 19, 2026, Myriad Genetics, Inc. agreed to sell its prenatal health business to Laboratory Corporation of America for $210 million in cash plus the value of inventory at closing. | 2026-10-20 | 2026-10-19 | |
| 8-K | Myriad Genetics agreed to pay former Chief Commercial Officer Brian Donnelly $1,322,294 in severance and accelerate time-based equity vesting through two years after his September 21, 2026 separation, subject to an agreement effective October 14, 2026. | 2026-10-09 | 2026-10-06 | |
| 8-K | — | 2026-09-16 | 2026-09-15 | |
| Investor Event Transcript | — | 2026-09-10 | 2026-09-30 | |
| 10-Q | — | 2026-07-31 | 2026-06-30 | |
| 8-K | — | 2026-07-30 | — | |
| 8-K | — | 2026-06-23 | 2026-06-17 | |
| 8-K | — | 2026-06-04 | — | |
| 10-Q | — | 2026-05-06 | 2026-03-31 | |
| 8-K | — | 2026-05-05 | — | |
| DEF 14A | — | 2026-04-14 | 2025-12-31 | |
| DEFA14A | — | 2026-04-14 | — | |
| ARS | — | 2026-04-14 | 2025-12-31 | |
| 10-K | — | 2026-02-24 | 2025-12-31 | |
| S-3 | — | 2026-02-24 | — | |
| 8-K | — | 2026-02-23 | — | |
| 8-K | — | 2026-01-12 | — | |
| 10-Q | — | 2025-11-04 | 2025-09-30 | |
| 8-K/A | — | 2025-11-04 | 2025-11-03 | |
| 8-K | — | 2025-11-03 | — | |
| 8-K | — | 2025-10-07 | 2025-10-01 | |
| 8-K | — | 2025-10-03 | 2025-09-29 | |
| 8-K | — | 2025-08-18 | 2025-08-15 | |
| 10-Q | — | 2025-08-06 | 2025-06-30 | |
| 8-K | — | 2025-08-05 | — | |
| 8-K | — | 2025-07-31 | — | |
| 8-K | — | 2025-06-05 | — | |
| 10-Q | — | 2025-05-07 | 2025-03-31 | |
| 8-K | — | 2025-05-06 | — | |
| DEFA14A | — | 2025-04-09 | — | |
| DEF 14A | — | 2025-04-09 | 2024-12-31 | |
| ARS | — | 2025-04-09 | 2024-12-31 | |
| 10-K | — | 2025-02-28 | 2024-12-31 | |
| 8-K | — | 2025-02-24 | — | |
| 8-K | — | 2025-01-15 | — | |
| 8-K | — | 2024-12-10 | — | |
| 8-K | — | 2024-11-26 | — | |
| 10-Q | — | 2024-11-08 | 2024-09-30 | |
| 8-K | — | 2024-11-07 | — | |
| 8-K | — | 2024-10-09 | — | |
| 8-K | — | 2024-09-04 | — | |
| 10-Q | — | 2024-08-07 | 2024-06-30 | |
| 8-K | — | 2024-08-06 | — | |
| 8-K | — | 2024-06-06 | — | |
| 8-K | — | 2024-06-03 | — | |
| 10-Q | — | 2024-05-08 | 2024-03-31 | |
| 8-K | — | 2024-05-07 | — | |
| DEF 14A | — | 2024-04-17 | 2023-12-31 | |
| DEFA14A | — | 2024-04-17 | — | |
| ARS | — | 2024-04-17 | 2023-12-31 |
Showing 1–50 of 130 filings
Key facts
CIK
899923
CUSIP
62855J104
13F (30d)
25 filings
25 filers
Visit website
Investor relations